Compare Chubb Ltd (CB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs TG Therapeutics Inc — how do they compare? Chubb Ltd trades at $344.89 (market cap $133.90B), while TG Therapeutics Inc trades at $49.69 (market cap $7.64B). The key difference: Chubb Ltd is far larger — about 17.5× TG Therapeutics Inc's market cap, and Chubb Ltd pays a 1.18% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CB | TGTX | |
|---|---|---|
Market Cap | $133.90B | $7.64B |
Sector | Financials | Health |
52-Week High | $363.50 | $59.06 |
52-Week Low | $268.20 | $26.94 |
Enterprise Value | $154.74B | $7.84B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chubb (CB) trades at $345.53, down 0.8% on the day, with a neutral technical signal. The stock shows strong fundamentals, with Q2 2026 EPS beating estimates at $7.26, revenue growth to $59.78B in 2025, and a net income margin of 17.96%. Analyst consensus is bullish with a $366.83 price target, and recent news highlights strategic partnerships and leadership appointments.
The outlook for CB is positive, supported by consistent earnings beats, robust profitability, and a favorable analyst stance. Key risks include market volatility and competitive pressures in the insurance sector. The stock presents a value opportunity with a P/E of 12.3, but investors should monitor macroeconomic factors affecting the industry.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
